204 related articles for article (PubMed ID: 9111826)
21. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group.
Koo J
Br J Dermatol; 1998 Jul; 139(1):88-95. PubMed ID: 9764154
[TBL] [Abstract][Full Text] [Related]
22. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study.
Thaçi D; Bräutigam M; Kaufmann R; Weidinger G; Paul C; Christophers E
Dermatology; 2002; 205(4):383-8. PubMed ID: 12444336
[TBL] [Abstract][Full Text] [Related]
23. Etanercept reduces symptoms and severity of psoriasis after cessation of cyclosporine therapy: results of the SCORE study.
Micali G; Wilsmann-Theis D; Mallbris L; Gallo G; Marino V; Brault Y; Germain JM
Acta Derm Venereol; 2015 Jan; 95(1):57-61. PubMed ID: 24682319
[TBL] [Abstract][Full Text] [Related]
24. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
[TBL] [Abstract][Full Text] [Related]
25. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.
Touw CR; Hakkaart-Van Roijen L; Verboom P; Paul C; Rutten FF; Finlay AY
Br J Dermatol; 2001 May; 144(5):967-72. PubMed ID: 11359382
[TBL] [Abstract][Full Text] [Related]
26. Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Italian Multicenter Study Group on Cyclosporin in Psoriasis.
Dermatology; 1993; 187 Suppl 1():8-18. PubMed ID: 8369579
[TBL] [Abstract][Full Text] [Related]
27. Low-dose cyclosporin improves the health-related quality of life in Japanese psoriasis patients dissatisfied with topical corticosteroid monotherapy.
Hashimoto T; Kawakami T; Tsuruta D; Hamada T; Natsuaki Y; Fukuda S; Koga H; Sogame R; Ohyama B; Ono F; Karashima T; Nakama T; Dainichi T; Ishii N; Yasumoto S
Australas J Dermatol; 2012 Aug; 53(3):202-6. PubMed ID: 22881466
[TBL] [Abstract][Full Text] [Related]
28. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin.
Pedraz J; Daudén E; Delgado-Jiménez Y; García-Río I; García-Díez A
J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):702-6. PubMed ID: 16836499
[TBL] [Abstract][Full Text] [Related]
29. Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis.
Lago E; Carneiro S; Cuzzi T; Magalhães G; Cássia F; Pessanha F; Ramos-e-Silva M
J Cutan Pathol; 2007 Jan; 34(1):15-21. PubMed ID: 17214849
[TBL] [Abstract][Full Text] [Related]
30. Cyclosporin in childhood psoriasis.
Perrett CM; Ilchyshyn A; Berth-Jones J
J Dermatolog Treat; 2003 Jun; 14(2):113-8. PubMed ID: 12775319
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
Ojeda R; Sánchez Regaña M; Massana J; Oliete R; Umbert P
J Dermatolog Treat; 2005; 16(4):238-41. PubMed ID: 16249146
[TBL] [Abstract][Full Text] [Related]
32. Intermittent etanercept therapy in pediatric patients with psoriasis.
Siegfried EC; Eichenfield LF; Paller AS; Pariser D; Creamer K; Kricorian G
J Am Acad Dermatol; 2010 Nov; 63(5):769-74. PubMed ID: 20833444
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM
J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
[TBL] [Abstract][Full Text] [Related]
35. Clinical usefulness and patient satisfaction for treatment with low-dose cyclosporin administration in patients with moderate psoriasis vulgaris.
Abe M; Ishibuchi H; Syuto T; Sogabe Y; Yokoyama Y; Ishikawa O
J Dermatol; 2007 May; 34(5):290-3. PubMed ID: 17408436
[TBL] [Abstract][Full Text] [Related]
36. Short- and long-term considerations concerning the management of plaque psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO).
Dermatology; 1993; 187 Suppl 1():19-29. PubMed ID: 8369576
[TBL] [Abstract][Full Text] [Related]
37. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
Papp KA; Menter MA; Raman M; Disch D; Schlichting DE; Gaich C; Macias W; Zhang X; Janes JM
Br J Dermatol; 2016 Jun; 174(6):1266-76. PubMed ID: 26800231
[TBL] [Abstract][Full Text] [Related]
38. Low-dose cyclosporin A in severe psoriasis. A double-blind study.
Van Joost T; Bos JD; Heule F; Meinardi MM
Br J Dermatol; 1988 Feb; 118(2):183-90. PubMed ID: 3280000
[TBL] [Abstract][Full Text] [Related]
39. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
40. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria.
Grattan CE; O'Donnell BF; Francis DM; Niimi N; Barlow RJ; Seed PT; Kobza Black A; Greaves MW
Br J Dermatol; 2000 Aug; 143(2):365-72. PubMed ID: 10951147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
